RET and medullary thyroid gland carcinoma: Recently, two MTC patients with the p.E632_L633del and p.D631_L633delinsS RET deletion, respectively, who were previously treated with cabozantinib and/or vandetanib, experienced a treatment benefit with selpercatinib, with a rapid biochemical response.